Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Palliation
•
Gastrointestinal Cancers
What dose constraint do you use for the ostomy site when treating a patient with close/adjacent disease?
Answer from: Radiation Oncologist at Academic Institution
I treat it the same as the GI tract structure that it is part of, typically either the jejunum or colon.
Sign in or Register to read more
6685
Related Questions
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
How would you manage a middle thoracic esophageal squamous cell carcinoma (tumor is 25-30 cm from carina) with a positive supra-clavicular lymph node?
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
Is there data to support worse surgical outcomes in short course RT followed by surgery vs. long course chemoradiation followed by surgery in rectal cancer?
How would you treat a patient with synchronous node positive prostate cancer (T3bN1M0) and oligometastatic rectosigmoid cancer (T4aN1M1) with a solitary liver metastasis?
How would you approach unexpected chemo breaks during planned neoadjuvant chemoradiation for esophageal adenocarcinoma?
Would you offer postoperative RT for pT2pN0 rectal cancer with close distal margin (within 2 mm) and only 6 lymph nodes obtained from surgery?
In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation when they have a single area of retroperitoneal metastasis?
What normal tissue dose constraints do you use when delivering up to 3 cycles of the palliative quad shot regimen for gynecologic pelvic malignancies?